TipRanks’ newly launched A.I Analyst tool has revealed two standout stocks, Alphabet (GOOGL) and ResMed (RMD), that could be top contenders for potential growth. Earning the highest overall scores from the tool, both stocks have been rated as Outperform.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
For context, TipRanks’ A.I. Stock Analysis delivers automated, data-driven evaluations of stocks based on multiple parameters to generate clear, easy-to-understand insights. The analysis includes Stock Overview, Positive and Negative Factors, Company Financials, Technical Analysis, and more. Designed for experienced investors and beginners, this tool helps users quickly identify a stock’s growth potential.
Let’s take a look at why these stocks are gaining traction under this AI-powered analysis.
Alphabet (GOOGL)
Alphabet is the parent company of Google and a global technology leader specializing in internet services, digital advertising, artificial intelligence (AI), and consumer tech products. With its dominant position in online search and digital advertising, Alphabet continues to invest heavily in innovation and emerging tech fields.
According to AI Stock Analysis, Alphabet has earned a score of 85 out of 100 with an Outperform rating. The strong score is based on its solid financials, steady growth across multiple business areas, and smart strategic moves. While there are some concerns around ad revenue and rising costs, the stock’s technical strength and reasonable valuation contribute to a positive overall outlook. Below is the screenshot that summarizes the positive and negative factors affecting the overall score.
Is Alphabet a Good Stock to Buy?
On Wall Street, analysts have a Strong Buy consensus rating on GOOGL stock based on 28 Buys and nine Holds assigned in the past three months. The average GOOGL price target of $197.69 per share implies a 19% upside potential.
See more GOOGL analyst ratings
ResMed (RMD)
ResMed is a global medical technology company specializing in cloud-connected devices and digital health solutions for treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in Australia and now headquartered in California, ResMed operates in over 140 countries.
ResMed also earns a score of 85 out of 100 with an Outperform rating on TipRanks AI Stock Analysis. ResMed’s high score is driven by its strong financial performance. Meanwhile, technical indicators also point to upward momentum, although the stock may face short-term fluctuations due to being slightly overbought. Additionally, its valuation appears fair, and the latest earnings call reinforces confidence in the company’s stability and future growth.
Is ResMed a Good Share to Buy?
According to TipRanks’ consensus forecast, RMD stock has a Moderate Buy rating, based on nine Buys and six Holds assigned in the last three months. The ResMed share price forecast is $264.44, which is 5% above the current trading level.
